Vimab Group Past Earnings Performance

Past criteria checks 0/6

Vimab Group has been growing earnings at an average annual rate of 35.7%, while the Professional Services industry saw earnings growing at 16% annually. Revenues have been growing at an average rate of 47.7% per year.

Key information

35.7%

Earnings growth rate

27.2%

EPS growth rate

Professional Services Industry Growth14.5%
Revenue growth rate47.7%
Return on equity-33.0%
Net Margin-6.0%
Last Earnings Update30 Jun 2024

Recent past performance updates

Recent updates

We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its Debt

Mar 14
We Think Vimab Group (STO:VIMAB) Is Taking Some Risk With Its Debt

Revenue & Expenses Breakdown

How Vimab Group makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:VIMAB Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 24376-23970
31 Mar 24370-12890
31 Dec 23342-4840
30 Sep 23295-14770
30 Jun 23255-26630
31 Mar 23237-27610
31 Dec 22227-34570
30 Sep 22211-28550
31 Dec 21206-24560
31 Dec 20217-46450

Quality Earnings: VIMAB is currently unprofitable.

Growing Profit Margin: VIMAB is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: VIMAB is unprofitable, but has reduced losses over the past 5 years at a rate of 35.7% per year.

Accelerating Growth: Unable to compare VIMAB's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: VIMAB is unprofitable, making it difficult to compare its past year earnings growth to the Professional Services industry (16.1%).


Return on Equity

High ROE: VIMAB has a negative Return on Equity (-33.03%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies